This study is currently not recruiting participants.

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease

Investigating the Safety of an Investigational Medication in Relapsed and Refractory Multiple Myeloma

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to evaluate the safety of an investigational new drug called carfilzomib, in patients with relapsed and refractory multiple myeloma.

Detailed description of study

The purpose of this study is to evaluate the safety of an investigational new drug called carfilzomib, in patients with relapsed and refractory multiple myeloma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Myeloma
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety of an investigational medication in patients with relapsed and refractory multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow, which are important for the immune system.

Participants in the study will receive the investigational medication to assess its safety. The study will monitor participants for any side effects or adverse reactions to the treatment.

  • Who can participate: Patients with relapsed and refractory multiple myeloma are eligible to participate. Specific age criteria are not mentioned.
  • Study details: Participants will receive the investigational medication to evaluate its safety. They will be monitored for any side effects or reactions to the treatment.
Updated on 19 Feb 2024. Study ID: 1109006848

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team